Soleno Therapeutics (NASDAQ:SLNO) Rating Lowered to “Hold” at Lifesci Capital

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by research analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald lowered shares of Soleno Therapeutics from an “overweight” rating to a “hold” rating and decreased their price target for the company from $123.00 to $53.00 in a report on Monday. HC Wainwright decreased their price target on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Robert W. Baird set a $107.00 price target on shares of Soleno Therapeutics in a report on Tuesday, January 13th. TD Cowen decreased their price target on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Finally, Wall Street Zen lowered shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.10.

Soleno Therapeutics Stock Up 32.3%

Shares of NASDAQ SLNO opened at $52.25 on Monday. Soleno Therapeutics has a 1 year low of $29.43 and a 1 year high of $90.32. The firm’s 50 day moving average price is $37.99 and its 200 day moving average price is $47.81. The firm has a market cap of $2.70 billion, a P/E ratio of 227.18 and a beta of -2.81. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. As a group, sell-side analysts anticipate that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Hedge Funds Weigh In On Soleno Therapeutics

Hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. purchased a new position in shares of Soleno Therapeutics in the 2nd quarter valued at $25,000. Danske Bank A S purchased a new position in shares of Soleno Therapeutics in the 3rd quarter valued at $27,000. Aster Capital Management DIFC Ltd purchased a new stake in Soleno Therapeutics during the 3rd quarter worth $37,000. Global Retirement Partners LLC increased its stake in Soleno Therapeutics by 519.0% during the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock worth $29,000 after buying an additional 519 shares during the period. Finally, Quarry LP purchased a new stake in Soleno Therapeutics during the 3rd quarter worth $47,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine Biosciences agreed to acquire Soleno for $53.00 per share in cash (~$2.9 billion), giving SLNO shareholders a ~34% premium to the pre-announcement close; the announcement is the primary driver of the stock’s gain. Neurocrine to Acquire Soleno Therapeutics Press Release
• Positive Sentiment: Market reaction: trading was briefly halted pending the announcement and SLNO subsequently climbed as the market priced in the cash consideration and takeover certainty. Stock Market Today: Soleno Climbs After Buyout
• Neutral Sentiment: Cantor Fitzgerald cut its price target to $53 (from $123) and has commented on the deal — the new target effectively aligns with the takeover price, leaving little analyst-upside post-announcement. Cantor Fitzgerald Downgrades
• Neutral Sentiment: Market commentary and valuation takes are appearing (analysis of the $50–$53 per-share tag); expect further debate over deal fairness and synergies. Seeking Alpha: Assessing the $50 Per Share Price Tag
• Negative Sentiment: Multiple securities class actions and investor-rights firms (Rosen, Hagens Berman, Bronstein, Levi & Korsinsky, Schall, etc.) have filed or opened investigations alleging misstatements around clinical trial information and the DCCR (VYKAT XR) program — litigation could create disclosure obligations, settlement risk and distract management. SLNO Investor Alert: Securities Fraud Lawsuit
• Negative Sentiment: Several shareholder law firms are investigating whether the transaction is fair to public shareholders and whether board fiduciary duties were satisfied — additional litigation or shareholder challenges could delay closing or increase costs. Halper Sadeh Investigation Notice

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.